Shorter proton therapy shows promise for lung cancer patients

NCT ID NCT01770418

Ongoing Disease control Sponsor: Proton Collaborative Group Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 21 times

Summary

This study tests a new way to give proton radiation for stage II-III non-small cell lung cancer. Instead of daily treatments over many weeks, patients receive higher doses over a shorter time (hypofractionation) along with standard chemotherapy. The goal is to find the safest highest dose and see if more patients survive at least 12 months. About 32 adults with good performance status are being enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Hampton University Proton Therapy Institute

Hampton, Virginia, 23666, United States
Maryland Proton Treatment Center

Baltimore, Maryland, 21201, United States
Northwestern Medicine Chicago Proton Center

Warrenville, Illinois, 60555, United States
Oklahoma Proton Center

Oklahoma City, Oklahoma, 73142, United States
Princeton ProCure Management LLC

Somerset, New Jersey, 08873, United States
University of Florida Proton Therapy Institute

Jacksonville, Florida, 32206, United States

Conditions

Explore the condition pages connected to this study.

LUNG NEOPLASMS